

## H2020-ITN THERACAT (765497)

<b>Work Package Number</b>	WP8	<b>Task Number</b>	T8.1-8.5	<b>Deliverable Number</b>	D8.2	<b>Lead Beneficiary</b>	EDI
<b>Deliverable Title</b>	Periodic report on dissemination (papers, patents, presentations in conferences) and participation in outreach activities (M12)						
<b>Contractual Delivery Date</b>	28/02/2019	<b>Nature</b>	Report		<b>Dissemination Level</b>	CO	
<b>Actual Delivery Date</b>	20/05/2019	<b>Contributors</b>	EDI and IBEC				

### Overview/Abstract

Periodic report on dissemination (papers, patents, presentations in conferences) and participation in outreach activities (M12).

### Explanation for large delay in submitting deliverable

N/A

### Led by

<b>Name</b>	Asier Unciti-Broceta	<b>Partner</b>	EDI	<b>Date</b>	10/05/2019
-------------	----------------------	----------------	-----	-------------	------------

### Reviewed by

<b>Name</b>	Lorenzo Albertazzi	<b>Partner</b>	IBEC	<b>Date</b>	17/05/2019
-------------	--------------------	----------------	------	-------------	------------

### Document Control

Issue #	Date	Changed Pages	Cause of Change	Implemented by
N/A	N/A	N/A	N/A	N/A

## 1. Report on dissemination and communication (M12)

Dissemination and communication activities conducted during the first year of the project were mainly aimed at spreading the existence of the project and its goals to both the scientific community and the general public, since most of the ESRs were just at the beginning of their PhD and starting their work within the THERACAT project, thus not having enough results to be disseminated/communicated yet.

### Communication activities


First communication activities performed within the project have consisted on (1) designing a project logo, (2) setting up the project website and (3) publishing some news on institution's beneficiary websites while ESRs were being recruited.

#### *Project logo*



#### *Project website (more information can be found in D8.1)*

<https://theracat.eu/>



#### *News*

Announcements on the institution's beneficiary websites

- [http://www.ibecbarcelona.eu/training-the-next-generation-of-experts-in-bio-orthogonal-catalysis-for-cancer-therapy /](http://www.ibecbarcelona.eu/training-the-next-generation-of-experts-in-bio-orthogonal-catalysis-for-cancer-therapy/)

- <https://www.biogelx.com/theracat-the-use-of-bio-orthogonal-catalysis-for-cancer-therapy/>
- <https://www.biogelx.com/introducing-biogelxs-new-cell-biologist-africa-galvez-flores/>
- <https://www.biogelx.com/the-theracat-project-gets-off-to-a-flying-start/>
- <https://www.ed.ac.uk/cancer-centre/news-and-events/news-2019/european-funding-success>

Mention in the description of beneficiaries' activities:

- <https://nanomedspain.net/institut-de-bioenginyeria-de-catalunya-ibec/>

Moreover, IBEC and EDI coordinated with Partner Organisation Cancer Research UK (CRUK) in order to design the best strategy on dissemination and communication activities to reach all audiences (both specialised and general public) to be implemented all along the project. CRUK is the world's leading cancer charity dedicated to saving lives through research, and its Research Information & Engagement team has an outstanding experience in communicating science to the general public. Thus, a plan for future communication activities to be conducted was discussed during Network Meeting 1, including:

- THERACAT social media accounts creation and management;
- Publication in divulgation blogs by the ESRs (e.g. <http://divulga.ibecbarcelona.eu/>);
- Preparation of videos explaining main goals of the project and societal implications for a general audience with the support from the TUE animation studio (D8.4);
- Participation of ESRs to science festivals, such as the European Researchers' Night (September 2019);
- Publication of at least two general press articles in EU magazines such as News, research\*eu, Horizon magazine (D8.5 and D8.9);
- Communication of the main project results via local media (university newsletters, local press, radio/TV programmes).

All ESRs and supervisors were strongly encouraged to participate in these activities as well as in any other outreach activity that may take place in their countries/institutions (e.g. Pint of Science, school visits to the institution, etc.).

## Dissemination activities

Concerning dissemination, please find below the activities that have been/will be soon performed:

- **Publication of results on scientific journals:** some beneficiaries such as BAS have already submitted the results obtained so far to be published in international peer-reviewed journals (currently under review);
- **International visits:** Prof. Unciti-Broceta was invited to Baylor University (Texas, US, 5<sup>th</sup> April, 2019), where he talked about the THERACAT project and the consortium (title of the talk: *“Bioorthogonal Catalysis: Overview, Applications and State-of-the-art”*);
- **Conferences:**
  - [RSEQ Biennial Meeting](#) (San Sebastian, SPAIN; May 28<sup>th</sup>, 2019): Prof. Ward, Prof. Roelfes and Prof. Unciti-Broceta will give talks about their corresponding THERACAT projects in the session entitled *“Artificial Metalloenzymes And Protein Design: Applications in Catalysis”*;
  - [Bioorthogonal & Bioresponsive 2019 Conference](#) (Edinburgh, UK; June 6<sup>th</sup>-7<sup>th</sup>, 2019): the project and some of its results will be presented by the Coordinator of the Network, Dr. Albertazzi, who will give a talk entitled *“A super-resolved look at nanomaterials”*. The conference is co-organised by partner EDI, Institute of Genetics & Molecular Medicine and RSC Chemical Biology & Bioorganic Group, and sponsored by partner CRUK and Company of Biologists, among others. Notably, the conference will also be attended by several of the ESRs working on the project.
  - [Unconventional Catalysis, Reactors and Applications](#) (Zaragoza, SPAIN; October 16<sup>th</sup>-18<sup>th</sup>, 2019): Prof. Unciti-Broceta will give a plenary lecture in this meeting entitled *“Biocompatible catalytic devices and bioorthogonally-activated prodrugs to mediate local chemotherapy”*, which focuses on the THERACAT project.

## 2. References

N/A